Point72 (DIFC)’s ALX Oncology ALXO Stock Holding History

Point72 (DIFC)’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,599	Closed	-$6.55K	–	1490
2024 Q3	$6.55K	Buy	3,599 +1,636	+83%	+$6.08K	﹤0.01%	1293
2024 Q2	$11.8K	Buy	+1,963	New	+$24.1K	﹤0.01%	1297

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Point72 (DIFC)'s ALXO Position: Q4 2024 in Review

Point72 (DIFC) sold out of ALX Oncology (ALXO) in Q4 2024, closing a stake of 3,599 shares — an estimated $6.55K sold.

Point72 (DIFC) first reported a position in ALXO in Q2 2024 and held it in 2 quarters. The position peaked at $11.8K in Q2 2024. 87 funds tracked by Wall St. Rank hold ALXO as of Q4 2024.

Point72 (DIFC) reported no remaining ALX Oncology position as of Q4 2024 after selling out during the quarter.
Point72 (DIFC) sold 3,599 ALX Oncology shares in Q4 2024, an estimated $6.55K.
Point72 (DIFC) first reported a position in ALX Oncology in Q2 2024 and held it in 2 quarters.
Point72 (DIFC)'s ALX Oncology position peaked at $11.8K in Q2 2024.
87 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2024.

Based on Point72 (DIFC)'s 13F filing for Q4 2024, filed 14 Feb 2025.